Journal of Infection and Chemotherapy最新文献

{"title":"Dilated common bile duct diameter as an indicator of bacteremia in patients with symptomatic common bile duct stones.","authors":"Kazuharu Kawano, Takayuki Otani, Toshikazu Abe, Toshihisa Ichiba, Keisuke Maeda, Yuji Okazaki, Hiroshi Naito","doi":"10.1016/j.jiac.2024.12.001","DOIUrl":"10.1016/j.jiac.2024.12.001","url":null,"abstract":"<p><strong>Background: </strong>The optimal timing and selection for blood culture collection in patients with acute cholangitis remains unclear. The relationship between common bile duct (CBD) diameter and the incidence of bacteremia in patients with CBD stones was elucidated.</p><p><strong>Methods: </strong>This single-center retrospective observational study included patients with symptomatic CBD stones who presented to the emergency department between January 2019 and December 2021. The primary endpoint was the incidence of bacteremia. The patients were divided into two groups based on bacteremia complications. The patient characteristics and CBD diameters were compared between the two groups to identify factors associated with bacteremia.</p><p><strong>Results: </strong>In total, 270 patients were analyzed, with bacteremia identified in 134 patients (50 %), and the median CBD diameter was 10.7 mm (IQR, 8.7-13.7). The CBD diameter was significantly larger in patients with bacteremia (median 12.4 mm [IQR, 9.9-15.7] vs. 9.7 mm [IQR, 8.2-11.7], P < 0.001) in univariate analysis. Multivariable analysis revealed that the CBD diameter was significantly associated with bacteremia (OR: 1.25, 95 % CI: 1.14-1.38, P < 0.010). The area under the ROC curves, representing the diagnostic accuracy of CBD diameter for indicating bacteremia, was 0.72 (95 % CI, 0.66-0.78) with a cut-off value of 11.2 mm.</p><p><strong>Conclusion: </strong>CBD dilation in patients with symptomatic CBD stones is significantly correlated with bacteremia. The CBD diameter cannot be assessed as the sole tool for detecting bacteremia; however, CBD dilation could be an indicator of bacteremia, assisting in the treatment strategy, regardless of the initial severity of cholangitis.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and microbiological characteristics of high-level daptomycin-resistant Corynebacterium species: A systematic scoping review.","authors":"Shinnosuke Fukushima, Hideharu Hagiya, Kazuyoshi Gotoh, Shuma Tsuji, Koji Iio, Hidemasa Akazawa, Osamu Matsushita, Fumio Otsuka","doi":"10.1016/j.jiac.2024.12.004","DOIUrl":"10.1016/j.jiac.2024.12.004","url":null,"abstract":"<p><strong>Introduction: </strong>Corynebacterium species potentially develop high-level daptomycin resistance (HLDR) shortly after daptomycin (DAP) administration. We aimed to investigate the clinical and microbiological characteristics of HLDR Corynebacterium infections.</p><p><strong>Methods: </strong>We first presented a clinical case accompanied by the results of a comprehensive genetic analysis of the isolate, and then performed a systematic scoping review. Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews, we searched for articles with related keywords, including \"Corynebacterium\", \"Daptomycin\", and \"Resistance\", in the MEDLINE and Web of Science databases from the database inception to October 25, 2024. Clinical case reports and research articles documenting the isolation of HLDR Corynebacterium species, defined by a minimum inhibitory concentration of DAP at ≥256 μg/mL, were deemed eligible for this review.</p><p><strong>Results: </strong>Of 80 articles screened, seven case reports detailing eight cases of HLDR Corynebacterium infections, as well as five research articles, were included. C. striatum was the most common species (7/9 cases, 77.8 %), and prosthetic device-associated infections accounted for 66.7 % of the cases. Duration of DAP administration before the emergence of HLDR isolates ranged from 5 days to 3 months; three-quarters of the cases developed within 17 days. Three HLDR isolates were genetically confirmed to have an alteration in pgsA2. The majority of the patients were treated with either glycopeptides or linezolid, with favorable outcomes. In vitro experiments confirmed that C. striatum strains acquire the HLDR phenotype at higher rates (71 %-100 %) within 24 h of incubation, compared to other Corynebacterium strains.</p><p><strong>Conclusion: </strong>DAP monotherapy, especially for prosthetic device-associated infections, can result in the development of HLDR Corynebacterium. Additional research is warranted to investigate the clinical implications of this potentially proliferating antimicrobial resistant pathogen.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of letermovir in preventing cytomegalovirus reactivation after cord blood transplantation.","authors":"Naoki Okada, Hiroyuki Muranushi, Kazuya Okada, Takayuki Sato, Tatsuhito Onishi, Yasunori Ueda, Takeshi Maeda","doi":"10.1016/j.jiac.2024.12.002","DOIUrl":"10.1016/j.jiac.2024.12.002","url":null,"abstract":"<p><strong>Background: </strong>Cord blood transplantation (CBT) is associated with a high risk of cytomegalovirus (CMV) infection. Letermovir (LTV) is a prophylactic agent against CMV reactivation after CBT, but data on its effectiveness and the incidence of late CMV reactivation after LTV discontinuation are limited.</p><p><strong>Methods: </strong>A single-center retrospective observational study was conducted in 79 adult CMV-seropositive CBT recipients who received their first transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome from February 2016 to September 2022. Outcomes were compared between 45 patients who received LTV prophylaxis and 34 patients who did not.</p><p><strong>Results: </strong>The cumulative incidence of CMV reactivation was significantly lower in patients who received LTV prophylaxis at both day 100 (11.1 % vs. 82.4 %, p < 0.001) and 1 year (45.3 % vs. 82.4 %, p < 0.001). The incidence of late CMV reactivation after LTV discontinuation was 34.2 %. The cumulative incidence of CMV disease was comparable between patients who received and those who did not (0 % vs. 8.8 % at day 100, 2.3 % vs. 8.8 % at 1 year; p = 0.181). Multivariate analysis showed that LTV prophylaxis reduced the cumulative incidence of CMV reactivation (hazard ratio 0.20, 95 % confidence interval 0.09 to 0.42, p < 0.001).</p><p><strong>Conclusion: </strong>LTV prophylaxis is strongly associated with prevention of CMV reactivation after CBT. Due to the high incidence of late CMV reactivation, close monitoring is required after LTV discontinuation and extension of LTV prophylaxis beyond day 100 should be considered.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of mumps virus-specific antibodies: Comparison of three different enzyme immunoassays and neutralization test.","authors":"Yuka Mihara, Tetsuo Nakayama, Fumihiko Hattori, Midori Yamada, Tetsushi Yoshikawa","doi":"10.1016/j.jiac.2024.11.021","DOIUrl":"10.1016/j.jiac.2024.11.021","url":null,"abstract":"<p><strong>Introduction: </strong>We evaluated the application of a newly improved enzyme immunoassay (EIA) kit, Mumps IgG Seiken®, by comparing antibody responses to different EIA kits, and neutralization tests (NTs), using clinical samples.</p><p><strong>Methods: </strong>Serum samples were collected before and 4-6 weeks after vaccination from 128 children who had no history of mumps or mumps vaccination. Using three different EIA kits, Mumps IgG Seiken®, a commercial kit from Enzygnost®, and an in-house kit, mumps-specific IgG antibodies were measured. Anti-mumps antibody responses between each of the EIA kits and NTs were evaluated.</p><p><strong>Results: </strong>Before vaccination, all samples were seronegative, except for three serum samples measured by Mumps IgG Seiken®, which exhibited equivocal. The antibody-positivity rates and equivocal rates of Mumps IgG Seiken® post-vaccination (71.1 % and 23.4 %, respectively) were comparable to those of Enzygnost® (74.2 % and 19.5 %, respectively). However, antibody-positivity and equivocal rates were significantly higher and lower than those of in-house kit (51.6 % and 40.6 %, respectively) (p < 0.05). The concordance rates of the kit (68.7 %) were comparable to those of Enzygnost® (71.1 %) and higher than those of in-house-developed kit (58.6 %) (p < 0.05). The area under curve of the three EIA kits were 0.801, 0.804, and 0.859; however, the differences did not reach significance. Correlations of the values obtained using three EIA kits with NTs were 0.71, 0.61, and 0.78.</p><p><strong>Conclusion: </strong>The newly approved Mumps IgG Seiken® showed good correlation with NTs and had lower equivocal rates compared to in-house kit, comparable to Enzygnost®. This kit may be clinically acceptable for the evaluation of vaccine immunogenicity.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensitrelvir for the treatment of COVID-19: Final analysis of a post-marketing surveillance from Japan.","authors":"Noriko Hayashi, Eri Tsukimura, Eriko Ogura","doi":"10.1016/j.jiac.2024.12.003","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.12.003","url":null,"abstract":"<p><strong>Background: </strong>Ensitrelvir received approval in Japan for emergency use in the management of patients with coronavirus disease (COVID-19) in November 2022. A post-marketing surveillance (PMS) was conducted to evaluate the safety and effectiveness of ensitrelvir in Japanese real-world clinical practice, and the interim analysis results (data cutoff: July 20, 2023) have been published. This report describes the final analysis of the PMS for ensitrelvir in a Japanese clinical setting.</p><p><strong>Methods: </strong>A continuous survey method was used for this PMS (November 2022 to December 2023), and the observation period was 28 days from the start date of ensitrelvir administration. Patients with COVID-19 who received ensitrelvir for the first time and provided written informed consent to collect and use their data were included in this survey. The outcomes included patient characteristics, adverse drug reactions (ADRs), and time to resolution of COVID-19 symptoms.</p><p><strong>Results: </strong>A total of 3760 and 3638 patients were included in the safety and effectiveness analysis sets, respectively. In the safety analysis set, the mean±standard deviation age was 43.6±17.7 years, 48.5% were male, 97.5% had mild COVID-19, and 73.4% had a vaccination history. Of the 379 ADRs reported, 374 were not serious and 5 were serious. None of the ADRs resulted in sequelae or death. The median time to resolution of fever and all symptoms was 36.0 and 156.0 hours, respectively.</p><p><strong>Conclusion: </strong>This PMS including >3000 patients suggested the safety and effectiveness of ensitrelvir for the treatment of patients with COVID-19 in Japan, with no new safety concern.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and clinical features of patients with tick bites in the Japanese spotted fever-endemic zone.","authors":"Shinnosuke Fukushima, Takaomi Sumida, Osamu Kawamata, Yoshimi Hidani, Hideharu Hagiya","doi":"10.1016/j.jiac.2024.11.020","DOIUrl":"10.1016/j.jiac.2024.11.020","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to clarify the epidemiology and clinical features of tick bites in a Japanese spotted fever (JSF)-endemic area.</p><p><strong>Method: </strong>The clinical records of patients with tick bites were retrospectively reviewed based on a survey conducted at Numakuma Hospital, Fukuyama City, Hiroshima, Japan, from 2016 to 2023. Data on basic characteristics, visit dates, residential address, exposure activities, tick-bite sites, and prophylactic antimicrobial prescriptions for each patient with tick bites were collected at the JSF hotspot hospital.</p><p><strong>Results: </strong>A total of 443 patients with tick bites visited the hospital, of which data on 305 cases (68.8 %) were reviewed. The median age of these patients was 71 years, with a higher proportion of women (63.0 %). One-third of the patients had a preceding history of working in fields, whereas two-thirds had entered mountains or agricultural fields. Nearly 90 % of the patients visited the hospital from April to August, and the most common bite sites were the lower extremities (45.1 %). Most patients (76.1 %) resided in the southern area of Numakuma Hospital. Nearly all patients were prescribed prophylactic antibiotics (minocycline in 87.8 % of cases), and none subsequently developed JSF.</p><p><strong>Conclusion: </strong>Continued surveillance of patients with tick bites is warranted to better understand changes in the clinical impact of tick-borne diseases.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tazobactam/Ceftolozane (TAZ/CTLZ) and Relebactam/Imipenem (REL/IPM) susceptibility in Japan: nationwide surveillance of respiratory bacterial pathogens in 2019/20.","authors":"Katsunori Yanagihra, Dai Kurihara, Masahiro Kimata","doi":"10.1016/j.jiac.2024.11.019","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.11.019","url":null,"abstract":"<p><p>Tazobactam/ceftolozane (TAZ/CTLZ) and relebactam/imipenem/cilastatin (REL/IPM/CS) are expected to be effective for treating patients with antimicrobial-resistant infections, particularly gram-negative pathogens, but nationwide surveillance of these has not been investigated thoroughly in Japan. Pseudomonas aeruginosa (n=164), Klebsiella pneumoniae (n=141), and Haemophilus influenzae (n=156) isolated from respiratory infected patients in Japan from June 2019 through December 2020 provided by the Japanese Surveillance Committee were used. Antimicrobial susceptibility testing for TAZ/CTLZ, REL/IPM and comparator agents against isolates were carried out by broth microdilution methods according to the Clinical and Laboratory Standards Institute standard. The MIC_50/90 of TAZ/CTLZ against P. aeruginosa and K. pneumoniae were 0.5/1 μg/mL and 0.25/0.5 μg/mL, those of REL/IPM were 0.25/1 μg/mL and 0.25/0.5 μg/mL, respectively, and all isolates were susceptible to both drugs. Susceptible rates for P. aeruginosa to IPM, ceftazidime (CAZ), and levofloxacin (LVFX) were 84.1, 87.8, and 76.8%, and those of K. pneumoniae to tazobactam/piperacillin, CAZ, and LVFX were 98.6, 98.6, and 95.0%, respectively. The MIC_50/90 of TAZ/CTLZ for H. influenzae were 0.5/2 μg/mL, comparable to those of cefepime (CFPM), 1/2 μg/mL, but susceptible rate to TAZ/CTLZ and CFPM differed at 50.6 and 100%, respectively. This difference was estimated from the different clinical breakpoints between TAZ/CTLZ (0.5 μg/mL) and CFPM (2 μg/mL) and the epidemiological prevalence of β-lactamase negative ampicillin resistance (BLNAR), which is high in Japan but rare in the US/EU. Excellent in vitro activities for TAZ/CTLZ and REL/IPM against major causative gram-negative bacteria in RTI patients were observed.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases with extensively drug-resistant Salmonella Typhi infection returning from Pakistan.","authors":"Nobuaki Tsuyama, Naoki Okawa, Emiri Muranaka, Haruki Mito, Yuuichi Oshimoto, Yasunobu Endo, Ryota Hase","doi":"10.1016/j.jiac.2024.11.018","DOIUrl":"10.1016/j.jiac.2024.11.018","url":null,"abstract":"<p><p>We report two cases of patients with extensively drug-resistant Salmonella Typhi infection who had recently traveled to Pakistan. These cases suggest that obtaining a detailed travel history and considering the epidemiology of drug-resistant S. Typhi in the suspected area of acquisition is crucial for managing patients with typhoid fever.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aspergillus spondylodiscitis successfully treated with a long course of isavuconazole.","authors":"Francisco Javier Teigell Muñoz, Ana Sánchez-de Torre, Marta Jiménez-Fernández, Lorenzo Zuñiga Gómez, María Mateos-González, Abdulhamit Batiray Polat, Jesús Fortún Abete","doi":"10.1016/j.jiac.2024.11.017","DOIUrl":"10.1016/j.jiac.2024.11.017","url":null,"abstract":"<p><p>We present a case of spondylodiscitis caused by Aspergillus fumigatus, which we successfully treated with isavuconazole after voriconazole severe intolerance. Aspergillus spondylodiscitis is a severe and relatively rare form of extra-pulmonary invasive aspergillosis. Typically, voriconazole is the first-choice antifungal drug for treating Aspergillus osteomyelitis or spondylodiscitis. However, isavuconazole, a new antifungal medication, has been demonstrated as non-inferior to voriconazole in cases of invasive aspergillosis. It has the added benefits of fewer hepatobiliary, ocular, and cutaneous side effects. It generally does not demand serum level monitoring and poses fewer risks of drug interactions. Nonetheless, there are no studies yet that support its use in spondylodiscitis, and published experiences are very limited and based on isolated cases, albeit mainly positive. The case we present here aims to provide additional evidence on the efficacy and tolerability of isavuconazole in treating this condition.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Legionella Diagnostic Prediction Score in patients with SARS-CoV-2 Omicron pneumonia.","authors":"Naoyuki Miyashita, Futoshi Higa, Yosuke Aoki, Toshiaki Kikuchi, Masafumi Seki, Kazuhiro Tateda, Nobuko Maki, Kazuhiro Uchino, Hiroshi Kiyota, Akira Watanabe","doi":"10.1016/j.jiac.2024.11.016","DOIUrl":"https://doi.org/10.1016/j.jiac.2024.11.016","url":null,"abstract":"<p><p>Legionella pneumonia is an important cause of community-acquired pneumonia (CAP). The Japanese Respiratory Society (JRS) pneumonia guideline 2024 proposed use of the Legionella Diagnostic Prediction Score for the management of CAP in adults. The committee for the JRS pneumonia guideline is required to verify the validity of the Legionella Diagnostic Prediction Score for the next revision. In addition, it is necessary to determine appropriate cutoff scores by examining all pneumonia cases. In the present study, we validated the usefulness of the Legionella Diagnostic Prediction Score using SARS-CoV-2 Omicron CAP. We analyzed 116 patients with L. pneumophila CAP and 947 patients with SARS-CoV-2 Omicron CAP. Among Omicron cases, the median Legionella Diagnostic Prediction Score was identical among BA.1, BA.2, BA.5, XBB lineage, BA.2.86 and JN.1 subvariants. The median Legionella Diagnostic Prediction Score was significantly higher in the L. pneumophila CAP group than the SARS-CoV-2 Omicron CAP group (4 vs 1, p<0.0001). When targeting all 947 patients with Omicron subvariants, the diagnostic sensitivity and specificity for the presumptive diagnosis of L. pneumophila CAP were 90.5% and 90.8%, respectively, when a total score ≥ 3 points was set as the cutoff level. When the cutoff score was ≥ 4 points, the diagnostic sensitivity and specificity for presumptive diagnosis of L. pneumophila CAP were 76.7% and 99.6%, respectively. Our results demonstrated that the Legionella Diagnostic Prediction Score had good diagnostic ability during the SARS-CoV-2 Omicron variant epidemic period. To set optimal indicators and cutoff values for the Legionella Diagnostic Prediction Score, the policy of the committee for the JRS pneumonia guideline is to continue testing for all pneumonia types.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142710488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}